Business Context and Reporting Period
This Form 8-K Current Report was filed by Syndax Pharmaceuticals, Inc. on February 12, 2020. The filing details compensation decisions approved by the Board of Directors regarding named executive officers and non-employee directors, including cash bonuses, salary adjustments, equity awards, and amendments to severance benefits.
Key Financial Metrics
The filing does not provide revenue, profit, cash flow, margin, debt, or liquidity metrics. It focuses exclusively on executive compensation and equity grant details.
- Stock Price: $9.47 per share (closing price on February 12, 2020, used as the exercise price for new options).
- 2019 Cash Bonuses Approved:
- Briggs W. Morrison (CEO): $262,375
- Michael A. Metzger (President/COO): $252,000
- Michael L. Meyers (SVP, CMO): $152,770
- 2020 Annual Base Salaries (Effective Jan 1, 2020):
- Briggs W. Morrison: $600,547
- Michael A. Metzger: $576,800
- Michael L. Meyers: $437,100
Material Changes and Equity Awards
The Board approved significant equity grants and changes to compensation structures:
- Stock Option Grants (Vesting over 48 months):
- Briggs W. Morrison: 194,000 shares
- Michael A. Metzger: 140,000 shares
- Michael L. Meyers: 50,825 shares
- Restricted Stock Unit (RSU) Grant: Michael A. Metzger received 15,000 shares vesting annually over 4 years.
- Severance Benefit Amendments:
- Dr. Meyers and Richard P. Shea: 9 months of salary and benefits upon termination without Cause or for Good Reason (absent Change in Control).
- Dr. Morrison and Mr. Metzger: 18 months of salary and 1.5x annual bonus target upon termination without Cause or for Good Reason in the event of a Change in Control.
- Non-Employee Director Compensation:
- Annual option grants set at 24,000 shares for members and 44,000 shares for the Chair.
- Increased annual retainers for committee members and chairs (ranging from $5,000 to $20,000 additional).
Guidance, Outlook, and Risks
The filing contains no financial guidance, market outlook, or discussion of operational risks. It notes that amended and restated employment agreements and the full text of the amended Non-Employee Director Compensation Policy will be filed as exhibits to the Quarterly Report on Form 10-Q for the period ended March 31, 2020.
Investor Verification Checklist
- Verify the final terms of the amended employment agreements in the upcoming Form 10-Q.
- Confirm the total dilution impact of the 384,825 new stock options and 15,000 RSUs granted.
- Review the specific definitions of "Cause," "Good Reason," and "Change in Control" in the new severance agreements to understand potential future liabilities.
- Monitor the vesting schedule compliance for the 48-month option grants and 4-year RSU grants.